GlaxoSmithKline plc Share Price Liquidnet
Stocks
GSK
GB0009252882
Pharmaceuticals
OTC Markets Traded|
Delayed
Liquidnet
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 09:35pm | FTSE 100 outperforms as oil price heads lower | AN |
| 09:28pm | European Stocks Close Mostly Lower in Monday Trading; US Treasury Secretary Scott Bessent to Give Details on Iran Sanctions | MT |
| Market Cap | 7.69TCr 10TCr 8.99TCr 8.41TCr 15TCr 10,04200Cr 15TCr 99TCr 39TCr 5,04300Cr 39TCr 39TCr 16,68500Cr | P/E 2026 * |
14.5x | P/E 2027 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 9.67TCr 13TCr 11TCr 11TCr 18TCr 12,63400Cr 18TCr 1,25200Cr 49TCr 6,34400Cr 50TCr 48TCr 20,99000Cr | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.64x |
| Free-Float |
92.75% | Yield 2026 * |
3.63% | Yield 2027 * | 3.91% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.40% | - | - | 10TCr | |
| -0.67% | +5.39% | +79.33% | +127.54% | 1,11900Cr | |
| +1.04% | +4.07% | +53.04% | +65.39% | 65TCr | |
| -0.17% | +5.67% | +27.45% | +80.40% | 47TCr | |
| -1.38% | +4.31% | +41.64% | +41.08% | 37TCr | |
| -0.52% | +3.53% | +24.32% | +40.27% | 30TCr | |
| -1.06% | +5.67% | +1.19% | +12.44% | 26TCr | |
| +1.03% | +5.83% | +53.86% | +72.96% | 24TCr | |
| -0.53% | +1.54% | -17.77% | -54.10% | 21TCr | |
| +0.42% | +5.63% | +28.55% | +92.24% | 18TCr | |
| Average | -0.21% | +5.17% | +32.40% | +53.14% | 42.22TCr | |
| Weighted average by Cap. | -0.17% | +5.40% | +45.70% | +72.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.63TCr 3.97TCr 3.71TCr 6.4TCr 4,43300Cr 6.47TCr 44TCr 17TCr 2,22600Cr 17TCr 17TCr 7,36500Cr | 3.55TCr 4.85TCr 4.15TCr 3.88TCr 6.7TCr 4,64000Cr 6.77TCr 46TCr 18TCr 2,33000Cr 18TCr 18TCr 7,70800Cr |
| Net income | 543.57Cr 741.59Cr 635.54Cr 594.55Cr 1.03TCr 71TCr 1.04TCr 7.04TCr 2.74TCr 36TCr 2.78TCr 2.72TCr 1,18000Cr | 648.43Cr 884.65Cr 758.14Cr 709.25Cr 1.22TCr 85TCr 1.24TCr 8.39TCr 3.26TCr 43TCr 3.32TCr 3.25TCr 1,40700Cr |
| Net Debt | 1.98TCr 2.71TCr 2.32TCr 2.17TCr 3.74TCr 2,59200Cr 3.78TCr 26TCr 9.98TCr 1,30100Cr 10TCr 9.94TCr 4,30600Cr | 1.71TCr 2.33TCr 1.99TCr 1.87TCr 3.22TCr 2,22900Cr 3.25TCr 22TCr 8.59TCr 1,11900Cr 8.74TCr 8.55TCr 3,70300Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
